

**Promotion Details:**  
**Kick Start Your Research Initiative in Cancer Genomics**  
**with BioSkryb Genomics and Ultima Genomics**

**Submissions now open until June 20, 2025**

BioSkryb Genomics, a pioneer in single-cell and ultra-low-input multi-omic solutions, and Ultima Genomics, a leader in scalable and cost-effective sequencing, announced a collaboration designed to accelerate next-generation oncology research. By combining BioSkryb's best-in-class single-cell amplification and multi-omic platforms with Ultima's ultra-high-throughput, cost-efficient sequencing technology, this collaboration aims to provide researchers with comprehensive, high-resolution insights into complex cancer genomics, ultimately driving discoveries that can inform improved patient outcomes.

As part of the collaboration, the companies are jointly announcing a grant program to advance research in important emerging areas of oncology that have been hampered by a lack of technologies to address critical research questions and by the high costs associated with sequencing. All cancer researchers are encouraged to apply for this newly launched joint grant program, which offers awards providing comprehensive multi-omic studies worth up to 2,000 single cell genomes at no cost. While all areas of oncology research are welcome, the program will focus on emerging and impactful research areas that are currently limited by technology constraints and high sequencing costs. Key areas of focus include:

- **Somatic Mosaicism and Clonal Heterogeneity** – Investigating how genetic variability within individual cells contributes to cancer evolution and therapeutic resistance.
- **Clonal Hematopoiesis and Disease Precursors** – Examining early markers of disease at single-cell resolution to inform early detection and intervention strategies.
- **Measurable Residual Disease and Drug-Resistant Cells** – Characterizing drug-resistant cell populations, mapping clonal architecture, and identifying new multi-omic biomarkers linked to therapy response, resistance, and relapse.
- **Ultra-Low-Input Sample Analysis (e.g., FNA Biopsies)** – Generating meaningful genomic and transcriptomic data from extremely limited sample inputs, enabling robust studies in clinical settings where sample material is scarce.
- Other areas of emerging research are encouraged to apply.

By leveraging their complementary expertise, both companies aim to empower the scientific community with the tools needed to unlock the complexities of cancer and usher in a new era of personalized medicine.

**Promotion Eligibility:**

- A. US-based Researchers in accredited institutions (including those under the National Institute of Health) will be eligible to submit proposals for the Promotion.
- B. Employees, officers, and directors of BioSkryb and their immediate family members are not eligible.

- C. NO PURCHASE NECESSARY TO ENTER OR WIN. Promotion is open to legal residents of the United States, including the District of Columbia who are at least 18 years old (or the age of majority in their jurisdiction, if greater than 18 years) at the time of entry.
- D. All valid entries must be received between April 22nd - June 20th, 2025.

**Promotion Details:**

For the Promotion a total of **two (2) grants** will be awarded and each grant includes:

- A. BioSkryb will provide free-of-cost single-cell amplification through preparation of sequencing-ready libraries in accordance with existing workflows and shall provide all such libraries to Ultima, which will perform library conversions (if applicable) and sequencing. These libraries can be used to generate genomic or multiomic (e.g., DNA + RNA) data for the Customers for a cumulative total of up to 2,000 cells with 1000 cells per Promotion. [BioSkryb Terms and Conditions](#).
- B. Ultima will provide free sequencing for up to 30x whole genome equivalents for a cumulative total of up to 2,000 cells with 1000 cells per Promotion that have undergone library preparation using BioSkryb reagents and passed Ultima library QC standards. [Ultima Terms and Conditions](#).

**Promotion Application and Selection Process**

- A. Applications will be accepted for 60 days following the public announcement of the Promotion (the "Promotional Period").
- B. Final awardees will be jointly selected by representatives from Ultima and BioSkryb.
- C. Selections will be based on scientific merit, relevance of research goals, and feasibility.

**Promotion Project Timeline**

- A. Customers must initiate and complete their projects by December 31, 2026.
- B. Any unused portion of the award after this period will expire unless otherwise agreed upon in writing.

**Promotion Non-Transferability**

- A. Promotions awarded are non-transferable and may not be sold, assigned, or transferred to any third party.

**Use of Promotion (*Grant*)**

- A. The sequencing-ready libraries must be generated using BioSkryb products.
- B. The Promotion may not be exchanged for cash or substituted for any other product or service.

**Promotion Publicity and Data Use by BioSkryb Genomics and Ultima Genomics**

- A. By accepting the Promotion, Customers agree to allow BioSkryb and Ultima to publicly disclose the recipients' names and general project descriptions and use anonymized data from the Customer's projects in publicly available marketing materials.
- B. Customers may be invited to participate in joint marketing efforts, including but not limited to case studies, webinars, or presentations.
- C. Any data generated under the Promotion may be used for scientific or promotional purposes with mutual agreement between the Parties.
- D. Neither Party will use the name, logo, or any other identifiers of the other Party or such other Party's trademarks in any advertising, publicity, or news release related to any actions or work

undertaken hereunder without the prior written consent of the other Parties.

**Applications can be submitted at: <https://forms.office.com/r/Wz0BAZ0rVL>**

**For questions, contact BioSkryb Genomics here: <https://www.bioskryb.com/contact/>**